Seizures in glioma patients: An overview of incidence, etiology, and therapies

Samudra, Niyatee; Zacharias, Tresa; Plitt, Aaron; Lega, Bradley; Pan, Edward

doi:10.1016/j.jns.2019.07.026

Cited by 36 publications

(46 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Glioma is a fatal brain tumor, which is the fourth leading cause of tumor-related death due to its invasive nature, molecular signals and the location of the central nervous system ( 27 ). In addition to causing death, seizures are common symptoms that seriously affect the lives of patients and their families ( 28 ). The researchers’ exploration of the mechanism of progression, diagnosis and treatment, and prognosis prediction are positively correlated with its harm to humans.…”

Section: Discussionmentioning

confidence: 99%

Identification of the potential biomarkers in patients with glioma: a weighted gene co-expression network analysis

et al. 2019

View full text Add to dashboard Cite

Abstract Glioma is the most common brain tumor with high mortality. However, there are still challenges for the timely and accurate diagnosis and effective treatment of the tumor. One hundred and twenty-one samples with grades II, III and IV from the Gene Expression Omnibus database were used to construct gene co-expression networks to identify hub modules closely related to glioma grade, and performed pathway enrichment analysis on genes from significant modules. In gene co-expression network constructed by 2345 differentially expressed genes from 121 gene expression profiles for glioma, we identified the black and blue modules that associated with grading. The module preservation analysis based on 118 samples indicates that the two modules were replicable. Enrichment analysis showed that the extracellular matrix genes were enriched for blue module, while cell division genes were enriched for black module. According to survival analysis, 21 hub genes were significantly up-regulated and one gene was significantly down-regulated. What’s more, IKBIP, SEC24D, and FAM46A are the genes with little attention among the 22 hub genes. In this study, IKBIP, SEC24D, and FAM46A related to glioma were mentioned for the first time to the current knowledge, which might provide a new idea for us to study the disease in the future. IKBIP, SEC24D and FAM46A among the 22 hub genes identified that are related to the malignancy degree of glioma might be used as new biomarkers to improve the diagnosis, treatment and prognosis of glioma.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of the potential biomarkers in patients with glioma: a weighted gene co-expression network analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that seizure recurrence following a prolonged seizure-free period could be suggestive of tumor progression, which would require prompt repeat imaging and re-evaluation of ASMs ( 11 , 52 ). If patients suffer from postoperative seizures without evidence of tumor recurrence, adjustment of ASMs should be considered after adequate AED blood levels are confirmed.…”

Section: Long-term Postoperative Management Of Grementioning

confidence: 99%

“…The mechanisms of glioma-related epilepsy are thought to be multifactorial and share common pathways with glioma growth processes ( 6 – 8 ). The pathogenesis of GRE involves many factors including tumor histology, tumor location, microenvironment; specific genetic alterations such as isocitrate dehydrogenase 1 (IDH1) gene mutation, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation; aberrant expression of potassium chloride cotransporter (KCC2), solute carrier family 7 member 11 (SLC7A11), glutamate, etc ( 8 – 11 ). In terms of postoperative seizure control, extent of resection, age, seizure type, seizure duration and Ki-67 expression have been identified as predictors ( 2 , 12 ).…”

Section: Introductionmentioning

confidence: 99%

“…Gross total resection remains an independent positive predictor for postoperative seizure control ( 2 , 12 , 13 ). However, uncontrolled seizures could occur in 20–40% of patients post resection ( 2 , 4 , 11 , 14 ). Recurrent seizures substantially impact quality of life, especially as newer therapies for gliomas have extended life expectancies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Diagnosis and Perioperative Management of Glioma-Related Epilepsy

2021

View full text Add to dashboard Cite

Gliomas account for more than half of all adult primary brain tumors. Epilepsy is the most common initial clinical presentation in gliomas. Glioma related epilepsy (GRE) is defined as symptomatic epileptic seizures secondary to gliomas, occurring in nearly 50% in high-grade glioma (HGG) patients and up to 90% in patients with low-grade glioma (LGG). Uncontrolled seizures, which have major impact on patients’ quality of life, are caused by multiple factors. Although the anti-seizure medications (ASMs), chemotherapy and radiation therapy are also beneficial for seizure treatment, the overall seizure control for GRE continue to be unsatisfactory. Due to the close relationship between GRE and glioma, surgical resection is often the treatment of choice not only for the tumor treatment, but also for the seizure control. Despite aggressive surgical treatment, there are about 30% of patients continue to have poor seizure control postoperatively. Furthermore, the diagnostic criteria for GRE is not well established. In this review, we propose an algorithm for the diagnosis and perioperative management for GRE.

show abstract

“…Furthermore, seizure control is often the most important predictor of quality-of-life in patients with recurrent LGG (Dunn-Pirio et al, 2018 ). Compared to standard antiepileptic medications, effectively inhibiting the development of gliomas is more conducive to control the onset of glioma-related seizures (Samudra et al, 2019 ). Moreover, Zhu et al ( 2012 ) indicated that CKs play a critical role in glioma diagnosis, prognosis, and therapy.…”

Section: Il-4 Glial Cells and Epilepsymentioning

confidence: 99%

Interleukin 4 Affects Epilepsy by Regulating Glial Cells: Potential and Possible Mechanism

Chen

Zhu

Lü

et al. 2020

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Epilepsy is a chronic brain dysfunction induced by an abnormal neuronal discharge that is caused by complicated psychopathologies. Recently, accumulating studies have revealed a close relationship between inflammation and epilepsy. Specifically, microglia and astrocytes are important inflammatory cells in the central nervous system (CNS) that have been proven to be related to the pathogenesis and development of epilepsy. Additionally, interleukin 4 (IL-4) is an anti-inflammatory factor that can regulate microglia and astrocytes in many aspects. This review article focuses on the regulatory role of IL-4 in the pathological changes of glial cells related to epilepsy. We additionally propose that IL-4 may play a protective role in epileptogenesis and suggest that IL-4 may be a novel therapeutic target for the treatment of epilepsy.

show abstract

Seizures in glioma patients: An overview of incidence, etiology, and therapies

Cited by 36 publications

References 78 publications

Identification of the potential biomarkers in patients with glioma: a weighted gene co-expression network analysis

Identification of the potential biomarkers in patients with glioma: a weighted gene co-expression network analysis

Clinical Diagnosis and Perioperative Management of Glioma-Related Epilepsy

Interleukin 4 Affects Epilepsy by Regulating Glial Cells: Potential and Possible Mechanism

Contact Info

Product

Resources

About